List of works - Bram Verstockt

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease

scientific article published on 07 September 2015

A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis

scientific article published on 28 April 2022

An unusual cause of severe, persistent diarrhoea

scientific article published in July 2017

Big data in IBD: big progress for clinical practice

scientific article published on 28 February 2020

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades

scientific article published on 01 June 2019

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

scientific article published on 01 February 2019

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

scientific article published on 01 March 2019

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?

scientific article published on 01 April 2020

Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply

scientific article published on 01 April 2019

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

scientific article

Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?

scientific article published on 3 February 2017

Estrogen receptor β controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage

scientific article published on 14 May 2018

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

scientific article published on 25 April 2018

Genetic Influences on the Development of Fibrosis in Crohn's Disease

scientific article

Genetics of inflammatory bowel disease: beyond NOD2.

scientific article published on 9 February 2017

Genome-wide association studies in Crohn's disease: Past, present and future.

scientific article published on 31 January 2018

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD

scientific article published on 01 March 2019

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients

scientific article published on 16 January 2019

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

scientific article published on 24 March 2019

Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

scientific article published on 01 March 2020

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

scientific article published on 15 August 2018

Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

scientific article published on 11 October 2019

Invited Editorial: Targeting Alpha 4 Beta 7, More Trafficking Inhibition Than We Thought?

scientific article published on 01 September 2020

Letter: Invasive nocardiosis, disseminated varicella zoster reactivation and pneumocystis jiroveci pneumoniae associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis

scientific article published on 12 September 2020

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

scientific article published on 01 October 2019

Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways

scientific article published on 02 May 2022

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis

scientific article published on 28 July 2020

Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease

scientific article published on 20 January 2019

New biologics and small molecules in inflammatory bowel disease: an update.

scientific article published on 26 May 2019

New treatment options for inflammatory bowel diseases

scientific article published on 19 March 2018

Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)

scientific article published on 15 October 2019

Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience

scientific article published on 20 August 2019

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease

scientific article published on 6 December 2017

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

scientific article published on 14 July 2018

Ten-year survival after endoscopic stent placement as a bridge to surgery in obstructing colon cancer.

scientific article published on June 2017

There is no benefit in routinely monitoring ANCA titres in patients with granulomatosis with polyangiitis

scientific article

Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease

scientific article published on 14 September 2020

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?

scientific article published on 08 July 2020

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

scientific article published on 01 July 2019

When IBD is not IBD

scientific article published on 26 September 2018

List of works by Bram Verstockt

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease

A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis

An unusual cause of severe, persistent diarrhoea

Big data in IBD: big progress for clinical practice

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?

Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?

Estrogen receptor β controls proliferation of enteric glia and differentiation of neurons in the myenteric plexus after damage

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Genetic Influences on the Development of Fibrosis in Crohn's Disease

Genetics of inflammatory bowel disease: beyond NOD2.

Genome-wide association studies in Crohn's disease: Past, present and future.

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing

Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

Invited Editorial: Targeting Alpha 4 Beta 7, More Trafficking Inhibition Than We Thought?

Letter: Invasive nocardiosis, disseminated varicella zoster reactivation and pneumocystis jiroveci pneumoniae associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis

Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease

New biologics and small molecules in inflammatory bowel disease: an update.

New treatment options for inflammatory bowel diseases

Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)

Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Ten-year survival after endoscopic stent placement as a bridge to surgery in obstructing colon cancer.

There is no benefit in routinely monitoring ANCA titres in patients with granulomatosis with polyangiitis

Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

When IBD is not IBD